Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

ClinicalTrials.gov ID: NCT04380688

Public ClinicalTrials.gov record NCT04380688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19

Study identification

NCT ID
NCT04380688
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
62 participants

Conditions and interventions

Conditions

Interventions

  • Acalabrutinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 12, 2020
Primary completion
Nov 15, 2020
Completion
Nov 15, 2020
Last update posted
Sep 12, 2021

2020

United States locations

U.S. sites
31
U.S. states
15
U.S. cities
28
Facility City State ZIP Site status
Research Site Anniston Alabama 36207
Research Site Mobile Alabama 36604
Research Site Escondido California 92029
Research Site Fullerton California 92835
Research Site Glendale California 91206
Research Site Newport Beach California 92663
Research Site New Haven Connecticut 06519
Research Site Washington D.C. District of Columbia 20010
Research Site Fort Lauderdale Florida 33308
Research Site Jacksonville Florida 32207
Research Site Jacksonville Florida 32209
Research Site Loxahatchee Groves Florida 33470
Research Site Fort Wayne Indiana 46804
Research Site Louisville Kentucky 40207
Research Site Annapolis Maryland 21401
Research Site Baltimore Maryland 21287
Research Site Bethesda Maryland 20889
Research Site Bethesda Maryland 20892-1374
Research Site Silver Spring Maryland 20910
Research Site Hackensack New Jersey 07601
Research Site Albany New York 12208
Research Site Buffalo New York 14263
Research Site New York New York 10029
Research Site The Bronx New York 10467
Research Site Philadelphia Pennsylvania 19140
Research Site Nashville Tennessee 38120
Research Site Houston Texas 77030
Research Site Houston Texas 77090
Research Site Tyler Texas 75701
Research Site Richmond Virginia 23298
Research Site Renton Washington 98055

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04380688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 12, 2021 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04380688 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →